Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Multiple sclerosis
•
Neurology
•
Neuro-immunology
Are there any precautions that should be taken when transitioning a patient with multiple sclerosis from one disease modifying therapy to another?
Related Questions
How frequently do you recommend ordering labs to monitor for side effects of disease-modifying therapies for multiple sclerosis?
At what degree of lymphopenia do you switch/discontinue dimethyl fumarate in patients with multiple sclerosis?
What are potential pitfalls in the use of OCT to support a diagnosis of multiple sclerosis?
For patients on anti-CD20 therapy for MS without frequent/opportunistic infections, are there serum IgG levels or ALC levels in which you pause or change therapy due to low levels?
What is your initial treatment paradigm for someone with both CNS and peripheral neurologic Sjogren’s?
What are red flags in an evaluation for possible multiple sclerosis that should prompt workup for genetic/inherited conditions?
What is your approach to immune management in opsoclonus-myoclonus-ataxia syndrome?
Would you proceed with anti-CD20 treatment in an MS patient who is VZV IgG negative in spite of vaccination in the last year?
Can you use a JAK inhibitor and Mavenclad in a patient with both multiple sclerosis and rheumatoid arthritis?
In a patient with strong serologic evidence of SLE presenting with isolated bilateral lower limb sensorimotor neuropathy, normal neuroimaging, and CSF, would you initiate cyclophosphamide with pulse-dose steroids upfront, or reserve escalation (e.g., plasma exchange or immunosuppressants) for cases refractory to steroids?
